ReviewBlood2017
The relative utilities of genome-wide, gene panel, and individual gene sequencing in clinical practice.
Review in Blood, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 60 citations in OpenAlex.
- Evaluating the Cost of Genomic Testing for Biomarker-Driven Therapies in Oncology.Oncology and therapy · 2026Article
- Genetic Landscape of Familial Melanoma.Genes · 2025Review
- Artificial intelligence in cardiology: a bibliometric study.American journal of translational research · 2024Article
- Gene mutation analysis using next-generation sequencing and its clinical significance in patients with myeloid neoplasm: A multi-center study from China.Cancer medicine · 2023Article
- Risk stratifying MDS in the time of precision medicine.Hematology. American Society of Hematology. Education Program · 2022Article
- Analysis of genetic variants in myeloproliferative neoplasms using a 22-gene next-generation sequencing panel.BMC medical genomics · 2022Article
- Patient-Specific Assays Based on Whole-Genome Sequencing Data to Measure Residual Disease in Children With Acute Lymphoblastic Leukemia: A Proof of Concept Study.Frontiers in oncology · 2022Article
- Networking for advanced molecular diagnosis in acute myeloid leukemia patients is possible: the PETHEMA NGS-AML projectHaematologica · 2021Article
- Interrogation of novel CDK2/9 inhibitor fadraciclib (CYC065) as a potential therapeutic approach for AML.Cell death discovery · 2021Article
- Familial thrombocytopenia due to a complex structural variant resulting in a WAC-ANKRD26 fusion transcript.The Journal of experimental medicine · 2021Article
- Targeted massively parallel sequencing of mature lymphoid neoplasms: assessment of empirical application and diagnostic utility in routine clinical practice.Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc · 2021Article
- Exosomes in the Healthy and Malignant Bone Marrow Microenvironment.Advances in experimental medicine and biology · 2021Article
- Article
- Article
- Prognostic roles of metabolic reprogramming-associated genes in patients with hepatocellular carcinoma.Aging · 2020Article
- Tumor mutation burden andAnnals of translational medicine · 2020Article
- Article
- Genetic Markers in Lung Cancer Diagnosis: A Review.International journal of molecular sciences · 2020Review
- Detection of the KITModern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc · 2020Article
- Clinical Utility of Next-Generation Sequencing in Acute Myeloid Leukemia.Molecular diagnosis & therapy · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 3 institutions in 1 country.
Funding
Abstract
Advances in technology that have transpired over the past 2 decades have enabled the analysis of cancer samples for genomic alterations to understand their biologic function and to translate that knowledge into clinical practice. With the power to analyze entire genomes in a clinically relevant time frame and with manageable costs comes the question of whether we ought to and when. This review focuses on the relative merits of 3 approaches to molecular diagnostics in hematologic malignancies: indication-specific single gene assays, gene panel assays that test for genes selected for their roles in cancer, and genome-wide assays that broadly analyze the tumor exomes or genomes. After addressing these in general terms, we review specific use cases in myeloid and lymphoid malignancies to highlight the utility of single gene testing and/or larger panels.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.